Novartis moved to exit its Fabhalta (iptacopan) lupus nephritis program, terminating a mid-stage trial cited as “strategic considerations” in a federal clinical trials database. The decision removes a key asset from the company’s late clinical lupus strategy and underscores how trial risk can quickly reshape pipeline plans. The lupus nephritis termination arrives as biopharma continues to face tighter scrutiny on development paths and endpoints in chronic immunology categories. For investors and partners, it signals likely reprioritization of resources toward other late-stage programs and more differentiated next bets.